復宏漢霖(02696.HK):HLX04-O用於濕性年齡相關性黃斑變性(wAMD)治療的國際多中心3期臨牀研究完成澳大利亞首例患者給藥
格隆匯4月19日丨復宏漢霖(02696.HK)發佈公吿,有關公司將漢貝泰® (貝伐珠單抗注射液)於全球範圍眼科治療用途和╱或療法的獨家權利許可給Essex Bio-Investment Limited(“億勝投資”)及珠海億勝生物製藥有限公司(與億勝投資合稱“Essex”),並約定與Essex共同開發相關產品。公司和Essex將分別承擔20%及80%與相關產品開發活動有關的成本及開支。近日,重組抗VEGF人源化單克隆抗體眼用注射液HLX04-O(“HLX04-O”)在濕性年齡相關性黃斑變性(wet age-related macular degeneration, wAMD)患者中開展的國際多中心3期臨牀研究完成澳大利亞首例患者給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.